Breaking News, Collaborations & Alliances

AnaptysBio, Momenta Enter Antibody Development Pact

To employ AnaptysBio's platform technology

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AnaptysBio, Inc. has initiated an antibody development program with Momenta Pharmaceuticals focused on the development of novel antibodies against an undisclosed target. AnaptysBio will receive an upfront fee in exchange for an option to acquire antibodies generated using its SHM-XEL platform against a specific therapeutic target. Financial terms were not disclosed.   “AnaptysBio’s platform technology and antibody development capabilities have been strongly validated by numerous succ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters